Dynamic Biosystems Secures RMB 130 Million Series A Funding Led by GL Ventures and Huimei Capital to Advance Single-Cell Multi-Omics Platforms

Suzhou Dynamic Biosystems Co., Ltd. (hereinafter referred to as “Dynamic Biosystems”) recently announced the completion of its RMB 130 million Series A financing round, jointly led by Hillhouse Venture Capital and Huimei Capital, with participation from Daoyuan Capital, Rongsheng Investment, and Mr. Lin Changqing, Chairman of Hotgen Biotech.

This round of financing will be used to accelerate the in-depth R&D and commercialization of the company’s multiple single-cell sequencing technology platforms (Paired-seq, Digital-seq, and Well-paired-seq), and to continuously explore the potential of precision medicine applications based on single-cell technologies through collaborations in oncology, eugenics and healthy reproduction, and biopharmaceuticals.

As a leading Chinese single-cell technology platform enterprise committed to independent innovation, Dynamic Biosystems is one of the few teams globally with in-depth coverage of foundational technologies across the entire single-cell workflow. In the cutting-edge field of single-cell multi-omics, the company has successfully overcome the limitations of Poisson distribution principles inherent in existing international single-cell sequencing technologies represented by 10x Genomics and BD, through innovative upstream methodologies. This breakthrough holds the promise of breaking foreign technological monopolies and accelerating the application of this disruptive precision medicine technology in scientific research, biopharmaceuticals, and clinical settings. Currently, the company has completed research trials for multiple technology platforms and is poised for large-scale market launch.

Professor Yang Chaoyong, Founder, Chairman, and Chief Scientist of Dynamic BiosystemsIt stated: “In the frontier fields of global technology, a strategy reliant on simple imitation of foreign technologies often fails to generate sustainable momentum for development or secure a foothold in international competition. Particularly as Chinese enterprises expand globally and access capital markets, they face patent-related challenges and various risks. Only by adhering to an independent innovation-driven development model can China hope to resolve ‘chokehold’ issues in key technological areas and achieve surpassing leadership.”

Li Jiacheng, CEO of Dynamic Biosystems“He expressed his sincere gratitude to the investors for their recognition and confidence in Dynamic Biosystems. Following this round of financing, the company will increase its investment in the research and development of single-cell sequencing technologies as well as in commercial operations, accelerate collaborations across various application fields, and promote data accumulation for single-cell technologies in diverse scenarios, including clinical applications. Upon completion of the production system certification at our Suzhou facility, we will initiate the clinical registration process for our RareCaSt single-cell enrichment and detection products. The company also plans to establish laboratories in major central cities successively, innovatively pioneering a series of unprecedented precision medicine applications based on single-cell technologies. Such leading efforts, leveraging Chinese ingenuity to benefit human health, are highly anticipated by many clinical experts.”

Hillhouse Ventures“Single-cell sequencing, as a tool capable of efficiently detecting heterogeneous gene expression across different cells, has been propelled to the forefront of our era, becoming an indispensable and powerful technology in the field of life sciences and medicine. With continuous technological improvements and breakthroughs, single-cell sequencing holds vast application prospects for precise disease research and therapy in the future. We believe that in the near future, single-cell sequencing technology will expand the horizons of precision medicine, enabling more patients to access affordable, specific, and highly effective therapies, thereby enhancing treatment efficacy and patient experience. Dynamic Biosystems remains committed to independent innovation in the field of single-cell sequencing. As a platform-oriented enterprise with broad development potential across multiple sectors, we look forward to supporting Chinese innovative biotechnology companies that have mastered core upstream technologies in their journey toward internationalization.”

Luo Rushu, Founding Managing Partner of Huimei Capitalstated: “After conducting extensive and in-depth comparative research in the field of single-cell detection, Huimei Capital has firmly chosen to partner with Dynamic Biosystems. This decision is driven by Dynamic Biosystems’ multiple innovative single-cell detection technology platforms, which overcome the limitations of Poisson distribution and achieve highly efficient single-cell analysis. Several of its key technical indicators are comparable to, or even surpass, those of world-class products. Furthermore, it is particularly commendable that Dynamic Biosystems has adhered to independent innovation since its inception, laying a solid foundation for global expansion. We look forward to the company’s continued innovative development, leveraging the performance characteristics and advantages of its platforms to become a distinctive Chinese force in the global single-cell detection sector, truly realizing its vision of ‘In China, for Global.’”

Zhang Dafeng, Founder of Daoyuan Capitalstated: “Dynamic Biosystems is an outstanding innovative enterprise built around a single-cell sequencing technology platform. Its founder, Professor Yang Chaoyong, is one of the world’s earliest senior experts involved in developing core technologies and components for single-cell sequencing. The company has established a differentiated product pipeline focused on the single-cell market and introduced a professional team for industrialization and commercial operations. As an investment fund specializing in healthcare, Daoyuan Capital is committed to identifying highly growth-oriented investment targets within the industry. We have strong confidence in the R&D capabilities of the Dynamic Biosystems team and look forward to the company developing blockbuster products with global competitiveness to benefit human health.”

Hongxing Erke Invests in Its Subsidiary Rongsheng Investmentstated: “We are highly optimistic about the prospects of Dynamic Biosystems in the field of single-cell sequencing. Its single-cell sequencing technology platform represents a rare breakthrough in China through source innovation, holds independent patents, breaks the monopoly held by foreign companies, and presents an opportunity to catch up with and surpass international competitors. It is a great honor to collaborate with the Dynamic team, led by Professor Yang Chaoyong and General Manager Li Jiacheng. We will continue to support Dynamic Biosystems in becoming a leading single-cell technology platform company, driving the advancement of single-cell technologies into the clinical market.”

Mr. Lin Changqing, Chairman of Hotgen Biotech“It was stated that the 2017 *Nature* special issue on single-cell analysis predicted that single-cell testing of blood samples or other biopsy specimens would become commonplace within a decade. After experiencing the ‘golden decade’ of next-generation sequencing, precision medicine is accelerating into the single-cell era. We are optimistic about the prospects of single-cell sequencing technology in clinical diagnostics. The team at Dynamic Biosystems has accumulated substantial expertise in upstream platform technologies for single-cell analysis, and we look forward to leveraging this capability to benefit patients in clinical diagnostics in the future.”

Regarding Dynamic Biosystems’ successful fundraising, existing shareholders Proxima Ventures and Dongyun Capital also extended their congratulations and expressed their expectations for the company’s future development.

Li Zhe, Managing Partner at Proxima Venturesstated: “As one of the earliest institutional investors in Dynamic Biosystems, we are delighted to see the company entering a phase of rapid development. The company has established an internationally leading, fully integrated single-cell multi-omics technology platform with independent intellectual property rights, achieving performance metrics at the global forefront. In response to market demands and industry pain points, it provides end-to-end solutions ranging from rare cell capture to single-cell omics analysis. Proxima Ventures remains bullish on the Dynamic Biosystems team’s sustained innovation capabilities in the field of single-cell sequencing. The completion of this financing round will accelerate Dynamic Biosystems’ emergence as a leading enterprise in the single-cell sector.”

Mr. Fan Hong, General Manager of Dongyun Venture CapitalIt stated: “In step with the industrial transformation and upgrading of the Wujiang Economic and Technological Development Zone, Dongyun Venture Capital is committed to laying out the biopharmaceutical industry chain, gradually forming an innovative drug platform and making comprehensive investments in biological raw materials, IVD, medical devices, and equipment. As a core investment of Dongyun, Dynamic Biosystems possesses fully independent intellectual property rights for its multi-platform single-cell detection technology, with multiple key technical indicators matching or even surpassing world-class products. The company is dedicated to promoting precision medicine and supporting life sciences and clinical medicine. We look forward to the company’s continuous innovation in the future, fully leveraging the performance characteristics and advantages of its platform to become a distinctive Chinese enterprise in the global single-cell detection field and serve the world.”

Dynamic Biosystems (dynamic-biosystems.com) is a comprehensive single-cell multi-omics technology platform company. It focuses on single-cell enrichment and detection platforms, single-cell sequencing technology platforms (Paired-seq, Digital-seq, and Well-paired-seq), and the ENCORE bioinformatics analysis algorithm platform, meeting the needs of single-cell multi-omics analysis in various application scenarios. The company is dedicated to exploring the immense potential of single-cell technologies in precision oncology, eugenics and healthy reproduction, and drug discovery. Committed to advancing precision medicine into the single-cell era, Dynamic Biosystems supports life sciences and clinical medicine, contributing Chinese expertise to the cause of human health!

GL Ventures, the venture capital platform under Hillhouse dedicated to early-stage innovative companies, covers key sectors including deep tech, software, biotechnology, new materials, emerging brands, and consumer technology. GL Ventures seeks out all entrepreneurs who are passionate about technology and believe in innovation. We aim to be the first call for founders seeking financing, and we look forward to accompanying them throughout their entrepreneurial journey.

Huimei Capital is a specialized fund focused on healthcare investment. Leveraging the ecosystem advantages of Huimei Medical Group, we invest in the healthcare ecosystem through multi-dimensional and holistic approaches, striving to build a professional investment platform with international vision and local execution capabilities, thereby helping early-stage and growth-stage healthcare companies achieve rapid development. We work closely with innovative healthcare companies experiencing high-speed growth, providing comprehensive strategic value-added services and systematic empowerment from a global perspective, and sharing Huimei Capital’s global business network and resource system with outstanding entrepreneurs.

Daoyuan Capital is a leading equity investment firm focused on the healthcare and medical sector. Daoyuan Capital manages 12 RMB-denominated funds and two USD-denominated funds, with investments in 69 high-quality portfolio companies. Among these, nine companies were listed on the Hong Kong Stock Exchange (HKEX) and the STAR Market between 2019 and 2020. As of 2021, Beikang Medical, a portfolio company of Daoyuan Capital’s funds, has been listed on the HKEX; additionally, two companies have passed the listing committee reviews of the STAR Market and the ChiNext Board, one has passed the HKEX listing hearing, and three companies have had their IPO applications accepted. It is expected that more than ten of Daoyuan Capital’s portfolio companies will be listed on major domestic and international stock exchanges within the next two years.

Rongsheng Investment was founded by Mr. Wu Rongguang, the founder of the ERKE brand, and focuses on investments in the biopharmaceutical sector. By continuously supporting and investing in biopharmaceutical companies with revolutionary innovative technologies that can improve people’s lives, it aims to drive development in the life sciences field.

Master’s degree; Professor-level Senior Engineer; MBA Entrepreneurship Mentor at the School of Economics and Management, Tsinghua University. Graduated from Xiamen University in June 1997 with a major in Applied Biochemistry, and from Tsinghua University in March 2017 with a major in Business Administration. Currently serves as Chairman and General Manager of Rejoyn Biotech Co., Ltd. and Beijing Hotgen Biotech Co., Ltd.

Proxima Ventures is a specialized investment firm focused on innovative medical technologies and disruptive biotechnologies, dedicated to serving exceptional innovative healthcare enterprises with significant growth potential. Managed and operated by a professional team with deep expertise in the medical industry, Proxima Ventures boasts diverse, internationalized professional knowledge, career backgrounds, and industry networks. The firm currently manages multiple RMB and USD-denominated funds. Proxima Ventures has established a leading healthcare entrepreneurship ecosystem, facilitating portfolio companies’ access to high-quality clinical and industrial resources, thereby achieving remarkable experience and outcomes.

Wujiang Dongyun Venture Capital Co., Ltd. was established in 2008, dedicated to early-stage and innovative investments, serving as an accelerator and stabilizer for the transformation and upgrading of local industries. Over more than a decade of angel investing, it has incubated three listed companies and nearly ten pre-IPO companies, achieving a current financial return on investment of over 50x, with the potential to exceed 100x. Its investment focus primarily centers on new energy, intelligent manufacturing, and biomedicine.